2 weeks Ago By Defense World Staff
Alliancebernstein L.P. increased its position in Olema Pharmaceuticals, Inc.
(NASDAQ:OLMA – Free Report) by 77.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 313,982 shares of the company’s stock after purchasing an additional 137,319 shares during the quarter.
Alliancebernstein L.P. owned approximately 0.
55% of Olema Pharmaceuticals worth $1,831,000 as of its most recent SEC filing. A number of other large investors have also added to or reduced their stakes in OLMA. JPMorgan Chase & Co.
boosted its holdings in shares of Olema Pharmaceuticals by 658.7% during the third quarter. JPMorgan Chase & Co.
now owns 181,032 shares of the company’s stock worth $2,162,000 after acquiring an additional 157,171 shares during the period. HighTower Advisors LLC bought a new position in Olema Pharmaceuticals during the fourth quarter worth about $510,000. Hennion & Walsh Asset Management Inc.
boosted its holdings in Olema Pharmaceuticals by 80.5% in the 4th quarter. Hennion & Walsh Asset Management Inc.
now owns 212,246 shares of the company’s stock valued at $1,237,000 after purchasing an additional 94,651 shares during the period. Barclays PLC increased its stake in Olema Pharmaceuticals by 105.0% during the 3rd quarter.
Barclays PLC now owns 94,915 shares of the company’s stock worth $1,133,000 after acquiring an additional 48,614 shares during the period. Finally, Pier Capital LLC bought a new position in Olema Pharmaceuticals in the 4th quarter valued at about $1,588,000. Institutional investors own 91.
78% of the company’s stock. Olema Pharmaceuticals Price PerformanceOLMA stock opened at $4.42 on Friday.
The stock has a market cap of $302.03 million, a price-to-earnings ratio of -2.02 and a beta of 2.
10. The company has a 50 day simple moving average of $4.21 and a 200 day simple moving average of $7.
12. Olema Pharmaceuticals, Inc. has a 1 year low of $2.
86 and a 1 year high of $16.62. Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last released its quarterly earnings data on Tuesday, March 18th.
The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.
12. On average, equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.
33 EPS for the current fiscal year. Analyst Ratings ChangesA number of research analysts recently issued reports on OLMA shares. HC Wainwright reissued a “buy” rating and issued a $30.
00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase & Co. decreased their price target on Olema Pharmaceuticals from $30.
00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, March 28th. Finally, Oppenheimer restated an “outperform” rating and set a $25.
00 price objective (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.Check Out Our Latest Stock Report on Olema PharmaceuticalsOlema Pharmaceuticals Profile (Free Report)Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.Further ReadingFive stocks we like better than Olema PharmaceuticalsWhat is the Nasdaq? Complete Overview with HistoryTariff Exemptions Set the Stage for a Taiwan Semiconductor Rally3 Stocks to Consider Buying in OctoberMitigating Tariffs: 3 Stocks to Gain From a Weaker U.S.
DollarThe Most Important Warren Buffett Stock for Investors: His OwnBroadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk.
